Glenmark received USFDA approval to launch Eribulin Mesylate Injection, bioequivalent to Halaven, expanding its oncology market presence.

• Halaven Injection U.S. sales reached $66.3 million in twelve months ending July 2025, highlighting the market opportunity.
• Glenmark’s first complex generic reinforces commitment to affordable oncology treatments while growing institutional product portfolio across therapeutic areas.
• The company operates globally in branded, generics, and OTC markets, focusing on oncology, respiratory, dermatology, and patient-centric, affordable healthcare solutions.